lululemon athletica inc. Announces Second Quarter Fiscal 2013 Results

VANCOUVER, British Columbia--(BUSINESS WIRE)-- lululemon athletica inc. (NAS: LULU) today announced financial results for the second quarter ended August 4, 2013.

For the thirteen weeks ended August 4, 2013:

• Net revenue for the quarter increased 22% to $344.5 million from $282.6 million in the second quarter of fiscal 2012.
• Comparable stores sales for the second quarter increased by 8% on a constant dollar basis.
• Direct to consumer revenue increased 39% to $49.4 million, or 14.3% of total Company revenues, in the second quarter of fiscal 2013, an increase from 12.5% of total Company revenues in the second quarter of fiscal 2012.
• Gross profit for the quarter increased 19% to $186.0 million, and as a percentage of net revenue gross profit decreased to 54.0% for the quarter from 55.1% in the second quarter of fiscal 2012.
• Income from operations for the quarter increased 12.5% to $79.0 million, and as a percentage of net revenue was 22.9% compared to 24.8% of net revenue in the second quarter of fiscal 2012.
• The tax rate for the quarter was 29.7% compared to 19.1% a year ago. The effective tax rate for the second quarter of fiscal 2012 reflected an adjustment of $7.2 million, reversing taxes provided for in the fourth quarter of fiscal 2011 through the first quarter of fiscal 2012.
• Diluted earnings per share for the quarter were $0.39 on net income of $56.5 million, compared to diluted earnings per share of $0.39 on net income of $57.2 million in the second quarter of fiscal 2012.

For the twenty-six weeks ended August 4, 2013:

• Net revenue for the first two quarters of fiscal 2013 increased 22% to $690.3 million from $568.3 million in the same period of fiscal 2012.
• Comparable stores sales for the first two quarters of fiscal 2013 increased by 8% on a constant dollar basis.
• Direct to consumer revenue increased 40% to $103.4 million, or 15.0% of total company revenues, in the first two quarters of fiscal 2013, an increase from 13.0% of total company revenues in the first two quarters of fiscal 2012.
• Gross profit for the first two quarters of fiscal 2013 increased 14% to $356.7 million, and as a percentage of net revenue gross profit was 51.7% for the first two quarters as compared to 55.1% in the same period of fiscal 2012.
• Income from operations for the first two quarters of fiscal 2013 increased 1% to $144.9 million, and as a percentage of net revenue was 21.0% as compared to 25.2% of net revenue in the same period of fiscal 2012.
• The effective tax rate for the first two quarters of fiscal 2013 was 29.7% compared to 28.0% a year ago.
• Diluted earnings per share for the first two quarters of fiscal 2013 were $0.71 on net income of $103.7 million, compared to diluted earnings per share of $0.71 on net income of $103.9 million the same period of fiscal 2012.

The Company ended the second quarter of fiscal 2013 with $610.3 million in cash and cash equivalents compared to $444.3 million at the end of the second quarter of fiscal 2012. Inventory at the end of the second quarter of fiscal 2013 totaled $163.0 million compared to $125.4 million at the end of the second quarter of fiscal 2012. The Company ended the quarter with 226 stores in North America and Australia.

Christine Day, lululemon's CEO, stated: "2013 continues to be the most important and most productive year in lululemon's history. We have not only worked our way back from the black luon setback, but have also added very talented people in important functions and have taken major steps forward on a number of key fronts including the expansion of our international and men's businesses and many logistical initiatives. In addition, our exclusive partnership with Noble announced today and additional sources for luon will help to ensure that lululemon remains a distinct leader in quality and innovation." Ms. Day continues: "We are well on our way to finishing 2013 as a much stronger company than when the year began. I am confident that the leadership currently in place coupled with a new CEO will have tremendous success leveraging the platform for growth."

Strategic global alliance with Noble Biomaterials

Today we announced a strategic global alliance for X-STATIC® with Noble Biomaterials. The partnership gives lululemon exclusivity to use Noble's X-STATIC® antimicrobial technology in our performance apparel. Noble has been a longstanding partner of lululemon, providing its X-STATIC® technology for our Silverescent® fabric since 2005. This unique opportunity allows us to continue to innovate our technical product with X-STATIC® and secure our leadership position in "anti-stink" athletic apparel. X-STATIC®'s properties have helped lululemon to set the industry standard by using the most powerful silver fabric technology to create our Silverescent® fabrics. Made with 99.9% pure metallic silver, X-STATIC® is designed to provide permanent odor protection by naturally inhibiting the growth of bacteria on the surface of fabrics. The silver fiber is woven directly into the garment and will not wash out over time through laundering.

Updated Outlook

For the third quarter of fiscal 2013, we expect net revenue to be in the range of $370 million to $375 million based on a comparable-store sales percentage increase in the mid-single digits on a constant-dollar basis. Diluted earnings per share are expected to be in the range of $0.39 to $0.41 for the quarter. This assumes 146.0 million diluted weighted-average shares outstanding and a tax rate of 30.0%.

For the full fiscal 2013, we now expect net revenue to be in the range of $1.625 billion to $1.635 billion and diluted earnings per share are expected to be in the range of $1.94 to $1.97 for the full year. This assumes 146.0 million diluted weighted-average shares outstanding and a tax rate of 30.0%.

Conference Call Information

A conference call to discuss second quarter results is scheduled for today, September 12, 2013, at 9:00 a.m. EST. Those interested in participating in the call are invited to dial 1-877-303-3203 approximately 10 minutes prior to the start of the call. The conference call will also be webcast live at www.lululemon.com. The webcast will be accessible on our website for approximately 30 days after the call.

About lululemon athletica inc.

lululemon athletica (NAS: LULU) is a yoga-inspired athletic apparel company that creates components for people to live long, healthy and fun lives. By producing products that help keep people active and stress free, lululemon believes that the world will be a better place. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback. For more information, visit www.lululemon.com.

Non-GAAP Financial Measure

Constant-dollar net revenue changes, which exclude the impact of changes in foreign exchange rates, is not a United States Generally Accepted Accounting Principle ("GAAP") performance measure. We provide constant-dollar net revenue changes because we use the measure to understand the underlying growth rate of revenue excluding the impact on a quarter-by-quarter basis of changes in foreign exchange rates, which are not under management's direct control. We believe that disclosing net revenue changes on a constant-dollar basis is useful to investors because it enables them to better understand the level of growth of our business.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on this non-GAAP financial measure, please see the table captioned "Reconciliation of Non-GAAP Financial Measure - Constant dollar changes" included in the accompanying financial tables, which includes more detail on the GAAP financial measure that is most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, such as statements regarding the effect of shipments of products that fail to comply with our technical specifications or that fail to conform to our quality control standards, the duration of any shortage of products available for sale in our stores or for delivery to guests or our ability to obtain replacement products in a timely manner, any expected loss of net revenue resulting from the inability to sell those products and related increased administrative and shipping costs, and our future financial condition or results of operations. In many cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "outlook," "believes," "intends," "estimates," "predicts," "potential" or the negative of these terms or other comparable terminology. These forward-looking statements are based on management's current expectations but they involve a number of risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of risks and uncertainties, which include, without limitation: our reliance on and limited control over third-party suppliers to provide fabrics for and to produce our products; negative publicity regarding any of our products or our the production methods of any of our suppliers or manufacturers; the effects of shipments of products that fail to comply with our technical specifications or that fail to conform to our quality standards; the effects of a shortage of products available for sale in our stores or for delivery to guests; an economic downturn or economic uncertainty in our key markets; increasing product costs and decreasing selling prices; our inability to anticipate consumer preferences and successfully develop and introduce new, innovative and updated products; our inability to accurately forecast customer demand for our products; our inability to manage our growth and the increased complexity of our business effectively; the fluctuating costs of raw materials; our highly competitive market and increasing competition; an unforeseen disruption of our information systems; our inability to deliver our products to the market and to meet customer expectations due to problems with our distribution system; our inability to cancel store leases if an existing or new store is not profitable; increasing labor costs and other factors associated with the production of our products in China; our inability to successfully open new store locations in a timely manner; our failure to maintain the value and reputation of our brand; our failure to comply with laws related to our human resources policies or other procedures; our failure to comply with trade and other regulations; our search for a new CEO and the possibility of losing the services of other key personnel; our competitors manufacturing and selling products based on our fabrics and manufacturing technology at lower prices than we can; our failure to protect our intellectual property rights; and other risks and uncertainties set out in filings made from time to time with the United States Securities and Exchange Commission and available at www.sec.gov, including, without limitation, our most recent reports on Form 10-K and Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements made herein speak only as of the date of this press release and the company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Contact:
ICR, Inc.
Joseph Teklits/Jean Fontana, 203-682-8200
or
Media Contact:
ICR, Inc.
Alecia Pulman, 203-682-8224

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:

Capstead Mortgage Corporation Declares a $0.31 Per Share Third Quarter 2013 Common Dividend and a $0.46875 Per Share Third Quarter 2013 Preferred Stock Series E Dividend

DALLAS--(BUSINESS WIRE)-- Capstead Mortgage Corporation (NYSE: CMO) announced today that it will pay a third quarter 2013 common dividend of $0.31 per common share on October 18, 2013 to stockholders of record as of September 30, 2013.

Capstead's Board of Directors also declared a third quarter 2013 dividend of $0.46875 per share on the Company's 7.50% Series E Cumulative Redeemable Preferred Stock (NYS: CMOPRE) . This dividend is payable on October 15, 2013, to Series E preferred stockholders of record as of September 30, 2013.

About Capstead

Formed in 1985 and based in Dallas, Texas, Capstead is a self-managed real estate investment trust for federal income tax purposes. The Company earns income from investing in a leveraged portfolio of residential adjustable-rate mortgage pass-through securities issued and guaranteed by government-sponsored enterprises, either Fannie Mae or Freddie Mac (together, the "GSEs"), or by an agency of the federal government, Ginnie Mae.

Cautionary Statement Concerning Forward-looking Statements

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words "believe," "anticipate," "expect," "estimate," "intend," "will be," "will likely continue," "will likely result," or words or phrases of similar meaning. Forward-looking statements are based largely on the expectations of management and are subject to a number of risks and uncertainties including, but not limited to, the following:

• changes in general economic conditions;
• fluctuations in interest rates and levels of mortgage prepayments;
• the effectiveness of risk management strategies;
• the impact of differing levels of leverage employed;
• liquidity of secondary markets and credit markets;
• the availability of financing at reasonable levels and terms to support investing on a leveraged basis;
• the availability of new investment capital;
• the availability of suitable qualifying investments from both an investment return and regulatory perspective;
• changes in legislation or regulation affecting exemptions for mortgage REITs from regulation under the Investment Company Act of 1940;
• changes in legislation or regulation affecting Fannie Mae, Freddie Mac, Ginnie Mae and similar federal government agencies and related guarantees;
• deterioration in credit quality and ratings of existing or future issuances of agency-guaranteed mortgage securities; and
• increases in costs and other general competitive factors.

In addition to the above considerations, our actual results and liquidity are affected by other risks and uncertainties which could cause actual results to be significantly different from those expressed or implied by any forward-looking statements included herein. It is not possible to identify all of the risks, uncertainties and other factors that may affect future results. In light of these risks and uncertainties, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. Forward-looking statements speak only as of the date the statement is made and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, readers of this document are cautioned not to place undue reliance on any forward-looking statements included herein.

Capstead Mortgage Corporation
Investor Relations:
Lindsey Crabbe, 214-874-2339

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:

ARIAD Announces Updated Data on AP26113 to Be Presented at the European Cancer Congress 2013 Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced that updated data from its Phase 1/2 trial of AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene 1 (ROS1), will be presented at the European Cancer Congress (the 38^th ESMO, 32^nd ESTRO, 17^th ECCO) being held in Amsterdam, September 27 to October 1, 2013.

Updated results from the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 28, 2013. The schedule and meeting location for the session, together with the abstract information, are listed below:

Oral Presentation at ECC 2013

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com

KEYWORDS:   United States  Europe  North America  Netherlands  Colorado  Massachusetts

INDUSTRY KEYWORDS:

Octagon 88 Resources Provides Shareholders With Manning Area Development Plan And Feasibility Studies For The Elkton Erosional Edge Project

ZUG, Switzerland--(BUSINESS WIRE)-- Octagon 88 Resources Inc., (OCTX) pleased to provide shareholders with the expanded version of the Manning Area Development Plan. The purpose of the expanded development plan is to define the sum of Octagon 88's acquired projects with a review specifically targeting the Elkton Erosional Edge Project including geology, exploitation plans, economics, specific goals, timelines and expected deliverables. The report outlines how the Company and partners have developed a highly trusted confidence geological model for the area; specifically for the lands with qualified third party economic models being derived from recent drilled wells, cores and seismic data.

Manning Area Development Plan

THE PRIMARY TARGET - THE ELKTON EROSIONAL EDGE, a shallow (460M) Mississippian aged Elkton high porosity medium permeability oil saturated Limestone. The simple erosional edge geologic model has proven to trap significant heavy oil reserves based upon well log and core data. With over 1.05 billion STB PIIP (third party estimate) of conventional heavy oil (13 - 15 deg API) and which can be developed with horizontal wells starting with primary recovery with subsequent infill drilling targeting 10% - 12 % recovery of the oil in place, followed by water flood for a further 8+% using secondary recovery techniques and then subsequent EOR projects. The project would be developed over 25+ years with peak oil rate occurring at the end of year 4 at over 30,000 bbl/d and over 200+ million bbls of recoverable oil using just primary and water flood during the first 25 yrs as studied in the following models. The well economics extend much longer and initial review shows 35+ years.

The estimated recovery rates are developed by internal industry professionals by compiling third party qualified studies with publicly released reports of comparable projects of other oil and gas companies.

THE SECOND TARGET - DEBOLT ZONE (erosional Limestone) - with an additional 200 million STB PIIP (third party estimate) of heavy oil with development plans yet to be fully developed however the exploitation plan is expected to be similar.

THE THIRD TARGET - BLUESKY OILSANDS CHANNELS (Marine sandstone) - The Bluesky Formation is the major producing zone in the Peace River area of northern Alberta. It is a sandstone that was deposited in the Lower Cretaceous within a marginal marine environment. Major operators south of Manning include Shell, Baytex, Penn West, Koch and Murphy. Internal total estimates for this project exceed 800+ STB PIIP, recent third party estimates already have confirmed 400+ million STB PIIP of conventional oil sands with potential for primary recovery to be followed with multiple 5-10,000 bbl/d thermal SAGD projects.

THE FOURTH TARGET(S) - down dip and immediately below the two erosional edges, the Elkton and Debolt the transition zones contain additional oil in limestone layers progressing from the highly oil saturated zones below the erosional edge to water bearing zones 20 to 30 meters deeper. These zones would be exploited in later stages using existing technology. An estimated 1-2 billion barrels PIIP (internal estimate) reside in these layers.
-Manning Area Development Plan - September 2013

As previously stated in an earlier release, the Company's technical team has confirmed that upon receipt of the production well license that it will initiate the well pad construction on the Eltkon Erosional Edge. The Company expects the license approval to be received at the end of September. Initial spudding of the first production well on the Elkton Erosional Edge will be based on drill rig availability.

For the complete Expanded Development Plan please click the link below:
www.octagon-88.com/feasibility-study

Octagon 88 Resources

Octagon 88 Resources, Inc. has acquired substantial light and conventional heavy oil assets in Northern Alberta. The CEC North Star Ltd project has been substantially de-risked which leads the company to emerge as a development stage oil and gas company. The current program schedule entails working with the operator of these properties to bring on production and cash flow through the company's direct working interests, and indirect investments spread throughout the projects.

Octagon 88 Resources is the largest publicly traded shareholder of CEC North Star currently holding 33 percent of its shares.

Forward-looking Statements:

This press release contains forward-looking statements concerning future events and the Company's growth and business strategy. Words such as "expects," "will," "intends," "plans," "believes," "anticipates," "hopes," "estimates," and variations on such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Forward looking statements in this press release include statements about our drilling development program. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the timing and results of our 2013 drilling and development plan. Additional factors include increased expenses or unanticipated difficulties in drilling wells, actual production being less than our development tests, changes in the Company's business; competitive factors in the market(s) in which the Company operates; risks associated with oil and gas operations in the United States; and other factors listed from time to time in the Company's filings with the Securities and Exchange Commission including the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Cautionary Note to U.S. Investors -- The United States Securities and Exchange Commission permits oil and gas companies, in their filings with the SEC, to disclose only proved reserves that a company has demonstrated by actual production or conclusive formation tests to be economically and legally producible under existing economic and operating conditions. We use certain terms in this press release, such as "probable," "possible," "recoverable" or "potential" reserves among others, that the SEC's guidelines strictly prohibit us from including in filings with the SEC. Investors are urged to consider closely the disclosure in our filings with the SEC.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130912005743/en/

Octagon 88 Resources Inc.
Tel:(+41) 79 237 6218
http://www.octagon-88.com
info@octagon-88.com
Investor Relations
Helvetic Prime
Alexander Baldi
Tel:(+41)79- 2569534
info@helveticprime.com
http://www.helveticprime.com

KEYWORDS:   United States  Europe  North America  Switzerland

INDUSTRY KEYWORDS:

WEX To Utilize Acumera As Part Of End-to-End Fuel Supply Chain Solution

SOUTH PORTLAND, Maine--(BUSINESS WIRE)-- WEX Inc. (NYS: WEX) , a leading provider of corporate payment solutions, today announced Acumera, a leader in Trusted Connection Services, will be supplying services to help improve network connection reliability and affordability for WEX Fuel Management customers.

WEX Fuel Management is the nation's leading solution for fuel wholesalers, retailers, fleets with on-site or bulk fuel and those buying fuel on the road. The new relationship between WEX and Acumera will provide an end-to-end fuel supply chain solution that includes connectivity to WEX Fuel Management's customers. Services provided by Acumera will generate a lower cost and simpler connectivity option than a traditional network with automatic tank gauge connectivity, virtually eliminating the need for dial-up modem connections that can be costly and unreliable.

The association between WEX and Acumera reflects the commitment by the two companies to provide every customer with highly integrated services. Tom Wagner, executive director, WEX Fuel Management said, "Our partnership with Acumera enables our customers to establish and maintain, with a high degree of integrity, the communications required to fulfill their fuel inventory and replenishment."

About WEX Inc.

WEX Inc.  (NYS: WEX) is a leading provider of corporate payment solutions. From its roots in fleet card payments beginning in 1983, WEX has expanded the scope of its business into a multi-channel provider of corporate payment solutions representing more than 7.4 million cardholders and offering exceptional payment security and control across a wide spectrum of business sectors. The Company's operations include WEX Bank, Fleet One, Pacific Pride, rapid! PayCard, Wright Express Australia, Wright Express New Zealand and CorporatePay Limited, England, as well as a majority equity position in UNIK S.A., Brazil. WEX and its subsidiaries employ more than 1,400 associates. For more information about WEX, please visit www.wexinc.com.

About Acumera

Founded in 2002, Acumera provides Trusted Connection Services to multi-site merchants, specializing in the reduction of headaches caused by network management and security issues. Customers are free to focus on running their businesses because Acumera actively manages their networks and provides unparalleled visibility and remote management capability. Acumera gets customers' stores, network clients and devices securely connected and keep them connected. In addition to network status, merchants have real-time insight into key operational measures, such as fuel inventory levels and environmental and food safety temperatures.

WEX Inc.
Jessica Roy, 207-523-6763
jessica.roy@wexinc.com

KEYWORDS:   United States  North America  Maine

INDUSTRY KEYWORDS:

UMeWorld Signs Agency Agreement for Cloud Based Adaptive Learning Educational Platform

UMeWorld commercializes its UMFun™ platform in China with a sales agency agreement in online education. This opportunity enables UMFun™ to reach over ten million targeted students starting October 2013. In the near term, the UMFun™ platform will increase the growth of UMeWorld and sets a template for future negotiations throughout China.

HONG KONG--(BUSINESS WIRE)-- UMeWorld Limited (OTCQB:UMEWF) is pleased to announce the signing of a sales agency agreement with Guangzhou KUMI Network Technology Co., Ltd ("KUMI") for UMFun™. It is a cloud-based adaptive learning educational platform, under its digital education business division.

KUMI operates the largest online gaming platform in Guangdong Province. Customers are between the ages of twelve and seventeen and spend an average of CNY$40 (US$7) a month on subscriptions. KUMI sells over one million charge cards monthly made available through a wide network of retail outlets to pay for subscriptions on their platform.

"We are excited to be partnering with KUMI, a powerful and successful marketer, to the twelve to seventeen age group. This agreement allows us to gain immediate access to our targeted customer group in Guangdong Province and establishes the partnering template for other provinces in China," said Michael Lee, President & CEO of UMeWorld Limited. "We are actively talking to other affiliates with parallel platforms to have UMFun™ made available to every K12 student in China in the near future."

About UMFun™

The UMFun™ (formerly SmartStar) is a cloud based, adaptive learning educational platform. The Platform name UMFun™ in the Chinese language means 'Full Mark'. It is a cost effective, engaging and fun to use assessment and tutoring platform that can intelligently analyze and adapt to a student's performance and personalizes the delivery of proprietary educational items according to the student's learning needs.

About UMeWorld

UMeWorld's mission is to facilitate the interaction between people -- "You" and "Me," through its digital platforms. Currently, UMeWorld operates UMeLook (www.umelook.com), an online video platform focused on bringing foreign video content to China. UMeLook plans to be a source of foreign video content for the Chinese viewer across any Internet-enabled device in China. UMeWorld intends to focus its future operations on digital media and the digital education market.

Forward Looking Statement

Statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. We assume no obligation to publicly update or revise any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, even if new information becomes available in the future. For a more detailed description of the risk and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission.

For more information, please contact:

Investor Relations
UMeWorld Limited
E-mail: info@UMeWorld.com

Or

Darren Bankston
678-455-6914
E-mail: darren@axiomir.com

UMeWorld Limited
Investor Relations
info@UMeWorld.com
or
Darren Bankston, 678-455-6914
darren@axiomir.com

KEYWORDS:   Asia Pacific  China

INDUSTRY KEYWORDS:

Dynamics Inc. Launches Upper Deck "Sports Collectible" Editions of Its ePlate® Electronic Credit Cards to Add to Its Exclusive Collection of UD Infinite Trading Cards

Upper Deck Collectors Can Now Have Exclusive Editions of Their ePlate® Visa® Credit Card in Addition to Earning Exclusive UD Infinite Packs of Basketball, Football and Golf Trading Cards

PITTSBURGH--(BUSINESS WIRE)-- This week Dynamics introduced another innovative reward experience for sports fans and collectors with new Upper Deck branded ePlate® credit cards. Each new ePlate® card features a unique Upper Deck Football, Baseball, Basketball, Hockey or Golf design on the front of the card. In an industry first - the magnetic stripe is no longer the plain dark brown stripe we have all grown accustomed to, but a sports graphic that compliments the front of the card.

Dynamics Launches Upper Deck "Sports Collectible" Editions Of Its ePlate(R) Electronic Credit Cards To Add To Its Exclusive Collection Of UD Infinite Trading Cards (Photo: Business Wire)

"Every day, our fans search online, communicate with other fans and attend sports shows in an effort to collect Upper Deck sports trading cards. Now with these new Upper Deck ePlate® cards, we're taking our collectors' enthusiasm for their favorite sport to a whole new level," said Jason Masherah, President of Upper Deck. "On top of the already successful UD Infinite cards packs which only ePlate® cardholders can earn, the new Upper Deck credit cards bring an instant recognition to our sports card collectors' passion for their favorite sport - every time they use the card."

"Sports collectors are always looking for one-of-a-kind experiences, experiences which provide them a connection to their favorite sport," said Jeff Mullen, CEO of Dynamics Inc. "What better way to extend that enthusiasm than to offer fans the only electronic card - the ePlate® - that powers their passion."

When the Upper Deck Experience™ reward is selected, consumers earn exclusive ePlate® digital trading cards for every $5 spent using their Dynamics ePlate® Visa® card. The digital cards are delivered instantly to a mobile phone after the completed purchase. When all digital cards in a set are collected, the consumer receives an exclusive UD Infinite foil pack. UD Infinite trading cards are only available to ePlate® card holders. Randomly inserted into packs are autographs of sports legends. Collectors can also trade or buy digital cards to complete their set even faster.

Dynamics will be showcasing its ePlate® sports cards at the upcoming Philadelphia Sportscard & Memorabilia Show in Valley Forge, Philadelphia and the Collector's Showcase of America (CSA) in Chantilly, Virginia. Consumers who apply for the ePlate® credit cards at these shows will earn an UD Infinite card pack.

The Dynamics ePlate® Visa® card and Upper Deck ePlate® Visa® cards are issued by UMB Bank and operate on the Visa® network. Customers may apply for the Dynamics Upper Deck cards by visiting www.dynamicsinc.com/upperdeck.

About Upper Deck:

Upper Deck is the leading sports and entertainment trading card and collectibles company. For more information on Upper Deck and its products please visit www.upperdeck.com.

About Dynamics Inc.:

Dynamics Inc., founded in 2007 by Jeff Mullen, designs and manufactures intelligent battery-powered payment devices and advanced payment platforms. The company won the $1M People's Choice Award at DEMO Fall 2010, four Finovate Best of Show awards, and Best in Show for Personal Electronics at the 2011 International CES show. Dynamics investors include Adams Capital Management and Bain Capital Ventures. For more information, visit www.dynamicsinc.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130912005768/en/

Upper Deck
Jodi Wasserman, 760-929-3188
jodi_wasserman@upperdeck.com
or
Dynamics Inc.
Adrian Sexton, 724-274-6484 x143
adrian.sexton@dynamicsinc.com

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

Primoris Services Corporation Announces New Contract Work Valued at over $155 Million

DALLAS--(BUSINESS WIRE)-- Primoris Services Corporation (NASDAQ Global Select: PRIM) ("Primoris" or "Company") today announced recent major contract awards totaling approximately $155 million. The new contracts and work authorizations secured by Primoris subsidiaries include pipeline and highway infrastructure projects throughout the continental United States.

In the East Construction Services Segment:

James Construction Group's Heavy Civil group was awarded new highway and transportation infrastructure projects across Louisiana and Texas totaling approximately $55 million. The duration of the new projects will extend through 2015.

In the West Construction Services Segment:

Rockford Corporation secured new contracts valued at over $100 million. The new Rockford contracts, which involve pipeline construction in Pennsylvania, Texas, and West Virginia, highlight the significant geographical range of the Rockford organization.

• The largest contract, located near Corsicana, Texas, consists of a 100 mile portion of the 500 mile Seaway 30" diameter pipeline, which will transport crude oil from the over supplied Cushing Hub to the Gulf Coast. The Seaway Crude Pipeline Company is a joint venture between Enterprise Products Partners, LLC, and Enbridge, Inc. The work is scheduled to start in the 3rd quarter of 2013 and should be completed during the first quarter of 2014.
• The second project, located near Clarksburg, West Virginia, consists of 2 miles of 24" diameter HDPE water line. This project started in the third quarter of 2013 and should be complete by the end of 2013.
• The third project involves 3.9 miles of 12" diameter gas pipeline in Susquehanna County, Pennsylvania. This project started in the third quarter of 2013 and should be complete by the end of 2013.

ABOUT PRIMORIS

Founded in 1946, Primoris, through various subsidiaries, has grown to become one of the largest construction service enterprises in the United States. Serving diverse end markets, Primoris provides a wide range of construction, fabrication, maintenance, replacement, water and wastewater, and engineering services to major public utilities, petrochemical companies, energy companies, municipalities, and other customers. With its acquisitions of James Construction Group in December 2009 and Rockford Corporation in November 2010, Primoris has doubled its size and the Company's national footprint now extends from Florida, along the Gulf Coast, through California, into the Pacific Northwest and Canada. For additional information, please visit www.prim.com.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including with regard to the Company's future performance. Words such as "estimated," "believes," "expects," "projects," "may," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements inherently involve risks and uncertainties, including without limitation, those detailed in the "Risk Factors" section and other portions of our Annual Report on Form 10-K, our Form 10-Q, and other filings with the Securities and Exchange Commission. Primoris does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Primoris Services Corporation
Kate Tholking, 214-740-5615
Director of Investor Relations
ktholking@prim.com

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:

ClearBridge American Energy MLP Fund Inc. Portfolio Composition as of August 31, 2013

NEW YORK--(BUSINESS WIRE)-- ClearBridge American Energy MLP Fund Inc. (NYS: CBA) announces its portfolio composition as of August 31, 2013.

Investment Objective: The Fund seeks to provide a high level of total return, with an equal emphasis on current distributions and capital appreciation.

Investment Strategy: The Fund seeks to achieve its objective by investing primarily in US-based master limited partnerships ("MLPs") in the energy sector. Initially, the Fund intends to focus its investments on MLPs that, in the Fund's opinion, are poised to benefit from the growing production and usage of natural gas, while minimizing exposure to commodity price fluctuations. Energy entities are engaged in the business of exploring, developing, producing, gathering, transporting, processing, storing, refining, distributing, mining or marketing natural gas, natural gas liquids (including propane), crude oil, refined petroleum products or coal.

ClearBridge American Energy MLP Fund Inc. is a non-diversified, closed-end management investment company which is advised by Legg Mason Partners Fund Advisor, LLC ("LMPFA") and subadvised by ClearBridge Investments, LLC ("ClearBridge"). LMPFA and ClearBridge are wholly owned subsidiaries of Legg Mason, Inc.

An investment in the Fund involves risk, including loss of principal. The Fund's concentration of investments in energy related MLPs subject it to the risks of investing in MLPs and the energy sector. Investment return and the value of shares will fluctuate.

Data and commentary provided in this press release are for informational purposes only. Legg Mason and its affiliates do not engage in selling shares of the Fund.

For more information, please call Investor Relations: 888-777-0102, or consult the Fund's web site at www.lmcef.com.

For ClearBridge American Energy MLP Fund Inc.
Investor Relations, 888-777-0102
www.lmcef.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

Westin Hotels Names Veteran Runner as the Brand's First-Ever Resident Running Concierge

Christopher Heuisler, Experienced Marathon Runner and Running Coach, Selected from a Pool of More Than 1,000 Highly-Qualified Applicants

STAMFORD, Conn.--(BUSINESS WIRE)-- It's the job runners have been training for all their lives and today, Westin Hotels & Resorts announced that Christopher Heuisler, a veteran runner who has competed in 25 marathons in 20 states, was chosen as the winner of its nationwide search for the first-ever RunWESTIN Concierge. Earlier this year Westin launched a search for an experienced, passionate runner to join them on the road and serve as the on-site running expert for Westin VIPs participating in select Rock 'n' Roll Marathon series events. Christopher beat more than 1,000 applicants to the finish line for the dream job after a month-long selection process that vetted final candidates through a series of application reviews and in-person interviews.

Westin Hotels Names the Brand's First-Ever Resident Running Concierge; Christopher Heuisler Selected as RunWESTIN Concierge from a pool of more than 1,000 Applicants. (Photo: Business Wire)

"After an extensive search for the ideal candidate, we are thrilled to have Christopher join the Westin team as our first RunWESTIN Concierge," said Brian Povinelli, Global Brand Leader, Westin Hotels & Resorts. "Not only does he have the marathon experience and impressive credentials we were looking for, but he is also an impassioned individual who will seamlessly connect with our guests and ultimately help them achieve their goals."

Christopher will make his first official appearance as the RunWESTIN Concierge this weekend at the Philadelphia Rock 'n' Roll Marathon. On September 21-22, Westin guests participating in the Montreal Rock 'n' Roll Marathon will have the first opportunity to take part in the VIP Marathon Package with Christopher as the official on-site running expert. As the RunWESTIN Concierge, Christopher will provide training tips through social channels, lead runners in a pre-race tour of the route and the routine warm-up run, greet runners at the finish line and provide race-recovery instruction and tips in the VIP Recovery Tent. In addition to Montreal, the resident RunWESTIN Concierge will appear at the Rock 'n' Roll Marathons in Denver, Los Angeles and Las Vegas.

From pre-race training to the finish line, Christopher will act as a personal marathon coach, engaging with runners and sharing expert training and race advice, in addition to leading warm-up runs and offering recovery tips for sore muscles. The Boston-based trainer will be responsible for sharing his in-depth knowledge of marathon running and training to improve performance and build and maintain rapport with Westin guests through social media outlets. In addition to his extensive marathon experience, the happily married father of two was most recently a tier-4 coach at Equinox Fitness Club - an honor bestowed only to 80 out of 1,800 personal trainers nationwide and indicating the highest level of client coaching. Serving as the tier-4 team's marathon expert, Christopher successfully coached over 20 clients in completing their first marathon.

Apart from his duties as an on-site coach for runners, Christopher will engage with Westin guests via social media, offering nutrition and training tips, setting race goals and providing inspiration for novices and veterans alike. Christopher will be connecting with guests across a variety of social platforms including Facebook, Instagram (@ChrisHeuisler) and Tumblr.

For more information on Westin Hotels & Resorts, please visit www.westin.com, Facebook or follow Westin on Twitter.

About Westin Hotels & Resorts

Westin Hotels & Resorts offers innovative programs that transform every aspect of a stay into a revitalizing experience. All Westin signature services - like the Heavenly Bed®, delicious SuperFoodsRx® and WestinWORKOUT® studio - have been designed with the guests' well-being in mind. Westin hotels,with more than 190 hotels and resorts in nearly 40 countries and territories, is owned by Starwood Hotels & Resorts Worldwide, Inc. (NYS: HOT) , one of the leading hotel and leisure companies in the world with 1,162 properties in nearly 100 countries and 171,000 employees at its owned and managed properties. Starwood is a fully integrated owner, operator and franchisor of hotels, resorts and residences with the following internationally renowned brands: St. Regis®, The Luxury Collection®, W®, Westin®, Le Méridien®, Sheraton®, Four Points® by Sheraton, Aloft®, and Element®. The Company boasts one of the industry's leading loyalty programs, Starwood Preferred Guest® (SPG®), allowing members to earn and redeem points for room stays, room upgrades and flights, with no blackout dates. Starwood also owns Starwood Vacation Ownership, Inc., a premier provider of world-class vacation experiences through villa-style resorts and privileged access to Starwood brands. For more information, please visit www.starwoodhotels.com.

About The Rock 'n' Roll Marathon Series

Organized by Competitor Group, the Rock 'n' Roll Marathon Series is the 'World's Largest Running Series' with more than 500,000 runners taking part in thirty-one destination events around the world. What started as a simple idea in 1998—the idea of making running fun-- soon transformed the U.S. running landscape by infusing the race course with live bands, cheer teams and entertaining water stations. The outdoor festivals encapsulate cities in their entirety and culminate with a finish line festival featuring a concert headlined by some of the best music acts around. Over the 16-year history of the series, charity partners have raised more than $287 million through the events for a variety of worthy causes. Today, the series of entertainment themed marathons and half-marathons has spread to 31 cities around the world and continues to enjoy great appeal for the traveling runner, tremendous local support and has firmly established itself as a dynamic running platform. For more information, or to register for an event, please visit RunRocknRoll.com or follow @RunRocknRoll on Twitter.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130912005241/en/

Starwood Hotels & Resorts
Nadeen Ayala, 203-351-2542
Nadeen.Ayala@starwoodhotels.com
or
Nancy J. Friedman PR
Chris Walters/Lisa Goldstein
212-228-1500
Chris@njfpr.com/Lisa@njfpr.com

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:

Synta Announces Presentations at the 2013 European Cancer Congress

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NAS: SNTA) today announced scheduled presentations at the 2013 ECCO-ESMO-ESTRO European Cancer Congress in Amsterdam, The Netherlands.

"Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels"

Abstract #: 3416
Date and Time: September 29, 2:00 - 4:30 PM CEST
Presenter: Dean Fennell, M.D., Ph.D., University of Leicester, United Kingdom

Interim results from the on-going GALAXY-1 Phase 2b/3 trial that were previously presented at ASCO 2013 will be reviewed. Additional details on the outcomes of patient subgroups with mutated KRAS and elevated LDH will also be provided.

Synta expects that results from a future analysis of the GALAXY-1 trial will be presented at the 2013 World Conference on Lung Cancer in Sydney, Australia during the week of October 27.

"Antimetastatic activity of ganetespib: Preclinical studies and assessment of progressions due to new lesions in the GALAXY-1 NSCLC trial"

Abstract #: 3517
Date: September 29, 2:00 - 4:30 PM CEST
Presenter: Vojo Vukovic, M.D., Ph.D., Synta Pharmaceuticals

Results demonstrating the anti-angiogenic and anti-metastatic properties of ganetespib in preclinical cancer models will be presented.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in "oncogene addiction" (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in trials in lung cancer, breast cancer, and other tumor types. The most common adverse event seen to date has been transient, mild or moderate diarrhea, which has been manageable with standard supportive care. Information on these trials can be found at www.clinicaltrials.gov. Ganetespib has received Fast Track designation from FDA for second-line treatment of non-small cell lung adenocarcinoma in combination with docetaxel.

About the GALAXY Program

The GALAXY (Ganetespib Assessment in Lung cancer with docetaXel) program consists of two randomized trials comparing the combination of ganetespib and docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More information about the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126 and NCT01798485).

About Lung Cancer

Lung cancer is the leading cause of cancer-related death in the world, accounting for nearly 1.4 million deaths in 2008, according to the World Health Organization. The five-year survival rate for this disease is approximately 16%; over half of people with lung cancer die within one year of being diagnosed. In the U.S., the American Cancer Society estimates that 228,000 cases of lung cancer will be diagnosed in 2013. Non-small cell adenocarcinoma comprises about 40% of all lung cancer.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and content of announcements and expected developments in the GALAXY-1 NSCLC trial, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com

KEYWORDS:   United States  Europe  North America  Netherlands  Massachusetts

INDUSTRY KEYWORDS:

Rexahn Awarded Patent in Europe for Cancer Drug Archexin ^®

Company to initiate Phase IIa clinical trials in Q4 of 2013

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the European Patent Office has granted the Company a patent, EP 1546180, for its clinical development candidate Archexin^® and its use for inhibiting the activated form of Akt-1 (phospho-Akt1)for the treatment of cancer.

Having successfully completed a Phase IIa clinical trial of Archexin in metastatic pancreatic cancer, Rexahn has conducted an extensive scientific, clinical and business analysis of other potential indications for additional Phase IIa clinical trials with the drug. Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type and plans on updating investors on the tumor type selection and Phase IIa trial timeline in the fourth quarter of 2013.

Peter D. Suzdak, Ph.D., Rexahn's Chief Executive Officer commented, "The issuance of this patent in Europe further strengthens our intellectual property estate on Archexin and provides IP protection and an enhanced position for Rexahn in a geography that represents a significant portion of the global oncology treatment market. This comes at a very important time for our Company, as we plan to embark on a new Phase IIa clinical trial for Archexin in the fourth quarter of this year."

About Archexin ^®

Archexin^® is a unique anti-cancer drug candidate which inhibits the cancer cell specific signaling protein phospho-Akt1. Phospho-Akt1 is over expressed in human cancer cells as compared to normal healthy tissue, and is involved in cancer cell growth, survival, angiogenesis, and drug resistance. Phospho-Akt1 has been shown to be present in most human cancer cell lines including in breast, colon, kidney, liver, lung, ovarian, pancreatic, prostrate, and stomach cancer cell lines. Archexin has been shown to inhibit the growth of human cancer cell lines in tissue culture and well as increase survival in various mouse cancer xenograft models.

Archexin has completed a Phase I clinical trial in cancer patients with solid tumors and was shown to be safe and well tolerated. The dose-limiting toxicity was a grade 3 fatigue. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and demonstrated a preliminary efficacy signal with a median survival of 9.1 months in evaluable patients.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin^®, RX-3117, and Supinoxin^TM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For Rexahn Pharmaceuticals
The Trout Group LLC
Tricia Truehart, 646-378-2953
ttruehart@troutgroup.com

KEYWORDS:   United States  Europe  North America  Maryland

INDUSTRY KEYWORDS:

Inland Real Estate Corporation Joint Venture Acquires Walmart-Anchored Shopping Centers in Milwaukee Market

OAK BROOK, Ill.--(BUSINESS WIRE)-- Inland Real Estate Corporation (NYS: IRC) today announced that its joint venture with Dutch pension fund advisor PGGM has acquired a portfolio of three Walmart-anchored shopping centers in the Milwaukee market for a total purchase price of $24.2 million, subject to future earn out payments. The portfolio totals approximately 174,500 square feet of retail space and was acquired from a regional developer in an off-market transaction.

"We continue to grow our platform through the acquisition of high-quality properties which strengthen the credit quality of our tenant base, as well as improve the diversification metrics and growth profile of our portfolio," said Scott Carr, chief investment officer for Inland Real Estate Corporation. "In addition, our ability to acquire these assets through our joint venture with PGGM allows us to leverage our partner's capital and achieve an attractive return on our equity, while retaining the option to increase our ownership interest in the future."

The portfolio includes the 62,307-square-foot Capital and 124^th shopping center in Wauwatosa, Wis.; the 71,927-square-foot Pilgrim Village shopping center in Menomonee Falls, Wis.; and the 40,302-square-foot Timmerman Plaza in Milwaukee, Wis. The property details are as follows:

• The Capitol and 124^th shopping center is 100 percent leased and anchored by a new 38,093-square-foot Walmart Neighborhood Market and a 13,000-square-foot Petco store. The city of Wauwatosa, Wis. is located approximately eight miles northwest of downtown Milwaukee. The shopping center is situated within a dense trade area, drawing from a population base of approximately 77,600 with an average household income of nearly $68,300 within a 3-mile radius.
• The 100 percent leased Pilgrim Village shopping center is anchored by a new 40,596-square-foot Walmart Neighborhood Market on a ground lease, with the balance of the center leased to a restaurant, hair salon and wine shop. Also included in the purchase are three outparcels to be developed. The city of Menomonee Falls is located approximately 14 miles northwest of downtown Milwaukee. Pilgrim Village is well-located at the busy intersection of Pilgrim Drive and Main Street next to Highway 45 and supported by average household income of more than $75,000 within a three-mile radius.
• The Timmerman Plaza property is shadow anchored by a new Walmart Supercenter and a Pick N Save grocery store (Roundy's Inc.). Included in the acquisition are a 12,000-square-foot store leased to Dollar Tree and a recently renovated 28,300-square-foot multi-tenant retail building. The property is located in the northwest corridor of Milwaukee and draws from a population base of approximately 99,300 with average household income of over $53,300 within a three-mile radius.

About Inland Real Estate Corporation

Inland Real Estate Corporation is a self-administered and self-managed publicly traded real estate investment trust (REIT) that owns and operates open-air neighborhood, community, power and lifestyle retail centers and single-tenant properties located primarily in the Midwestern United States. As of June 30, 2013, the Company owned interests in 154 investment properties, including 40 owned through its unconsolidated joint ventures, with aggregate leasable space of approximately 15 million square feet. For additional information, please visit www.inlandrealestate.com. To connect with Inland Real Estate Corporation via LinkedIn, please visit http://www.linkedin.com/company/inland-real-estate-corporation, or via Twitter at www.twitter.com/IRC_REIT.

Safe Harbor

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not reflect historical facts and instead reflect our management's intentions, beliefs, expectations, plans or predictions of the future. Forward-looking statements can often be identified by words such as "believe," "expect," "anticipate," "intend," "estimate," "may," "will," "should" and "could." Examples of forward-looking statements include, but are not limited to, statements that describe or contain information related to matters such as management's intent, belief or expectation with respect to our financial performance, investment strategy or our portfolio, our ability to address debt maturities, our cash flows, our growth prospects, the value of our assets, our joint venture commitments and the amount and timing of anticipated future cash distributions. Forward-looking statements reflect the intent, belief or expectations of our management based on their knowledge and understanding of the business and industry and their assumptions, beliefs and expectations with respect to the market for commercial real estate, the U.S. economy and other future conditions. These statements are not guarantees of future performance, and investors should not place undue reliance on forward-looking statements. Actual results may differ materially from those expressed or forecasted in forward-looking statements due to a variety of risks, uncertainties and other factors, including but not limited to the factors listed and described under Item 1A"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission (the "SEC") on February 28, 2013 as they may be revised or supplemented by us in subsequent Reports on Form 10-Q and other filings with the SEC. Among such risks, uncertainties and other factors are market and economic challenges experienced by the U.S. economy or real estate industry as a whole, including dislocations and liquidity disruptions in the credit markets; the inability of tenants to continue paying their rent obligations due to bankruptcy, insolvency or a general downturn in their business; competition for real estate assets and tenants; impairment charges; the availability of cash flow from operating activities for distributions and capital expenditures; our ability to refinance maturing debt or to obtain new financing on attractive terms; future increases in interest rates; actions or failures by our joint venture partners, including development partners; and factors that could affect our ability to qualify as a real estate investment trust. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Inland Real Estate Corporation Contacts:
Dawn Benchelt, Assistant Vice President/Investor Relations Director
(630) 218-7364
ir@inlandrealestate.com
or
Beth Hicks, Assistant Vice President/Marketing Director
(630) 954-4411
hicks@inlandrealestate.com

KEYWORDS:   United States  Europe  North America  Netherlands  Illinois  Wisconsin

INDUSTRY KEYWORDS:

GreenHunter Water Goes Operational on New Disposal Facility in Washington County, Ohio

100% Capacity Utilization Already Committed

GRAPEVINE, Texas--(BUSINESS WIRE)-- GreenHunter Resources, Inc. (NYSE MKT:GRH)(NYSE MKT:GRH.PRC) (the "Company"), a diversified water resource, waste management and environmental services company specializing in the unconventional oil and natural gas shale resource plays, announced today that its wholly-owned subsidiary, GreenHunter Water, LLC, began today commercial operations at a new salt water disposal (SWD) facility located in Newport, Washington County, Ohio. This riverside SWD has the potential to inject a minimum of 1,200 barrels per day (BBL/D) of oilfield brine. New field personnel have been hired to run the SWD facility.

The Newport SWD is strategically located in proximity to GreenHunter's existing Appalachian operations handling water logistics for both the Marcellus and Utica Shale Plays. With this new SWD facility, the Company's SWD capacity in the region has grown to over 13,000 BBL/D. Management is exploring options to develop pipeline infrastructure to access this specific facility, thereby eliminating truck transportation traffic and costs for our customers.

Management Comments

Commenting on the start of commercial operations at the Newport salt water disposal facility, John Jack, GreenHunter Vice President in the Appalachian region, stated, "We are excited to see the Newport SWD finally in commercial operation. We have been working on this project for over a year. Our oilfield customers have increased their demand for disposal capacity recently and we have been working hard to bring on additional water handling capabilities to alleviate the increased supply constraints being experienced in this region. We have a very exciting pipeline of developments that should keep our Oilfield Fluid Management Solutions™ infrastructure growing and help our customers in reducing their overall cost of water handling as they continue developing this tremendous domestic oil and gas unconventional resource."

About GreenHunter Water, LLC (a wholly owned subsidiary of GreenHunter Resources, Inc.)

GreenHunter Water, LLC provides Oilfield Fluid Management Solutions™. An understanding that there is no single solution to E&P fluids management shapes GreenHunter's technology-agnostic approach to services. In addition to licensing of and joint ventures with manufacturers of mobile water treatment systems (Frac-Cycle®), GreenHunter Water is expanding capacity of salt water disposal facilities, next-generation modular above-ground storage tanks (MAG Tank™), advanced hauling and fresh water barge logistics services—including 21st Century tracking technologies (RAMCAT^TM) that allow hydrocarbon producers to optimize the efficiency of their water resource management and planning while complying with emerging regulations and reducing cost.

For a visual animation of the Class II Salt Water Disposal well development and completion technique that is being utilized in GreenHunter Water's Appalachia, Eagle Ford, Mississippian Lime and Bakken SWD program, navigate to the video by clicking on "Salt Water Disposal Animation" button on the Operations tab at GreenHunterResources.com or click here.

Additional information about GreenHunter Water may be found at www.GreenHunterWater.com

Forward-Looking Statements

Any statements in this press release about future expectations and prospects for GreenHunter Resources and its business and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the substantial capital expenditures required to fund its operations, the ability of the Company to implement its business plan, government regulation and competition. GreenHunter Resources undertakes no obligation to update these forward-looking statements in the future.

GreenHunter Resources, Inc.
Jonathan D. Hoopes
Interim CEO, President and COO
1048 Texan Trail
Grapevine, TX 76051
Tel: (972) 410-1044
jhoopes@greenhunterresources.com

KEYWORDS:   United States  North America  Ohio  Texas

INDUSTRY KEYWORDS:

Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcinoma

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NAS: SNTA) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of ganetespib, the Company's lead Hsp90 inhibitor drug candidate, to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen. FDA's Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs that are intended to treat serious medical conditions and that demonstrate the potential to fill unmet medical needs.

"We are very pleased that FDA has granted this important designation to the ganetespib development program," said Safi Bahcall, President and CEO of Synta. "We look forward to continued progress and bringing ganetespib to cancer patients as quickly as possible."

Ganetespib is currently being evaluated as a treatment of non-small cell lung adenocarcinoma in the GALAXY program, consisting of the GALAXY-1 Phase 2b/3 all-comer trial and the GALAXY-2 Phase 3 trial enriched for patients most likely to benefit from ganetespib treatment.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in "oncogene addiction" (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in trials in lung cancer, breast cancer, and other tumor types. The most common adverse event seen to date has been transient, mild or moderate diarrhea, which has been manageable with standard supportive care. Information on these trials can be found at www.clinicaltrials.gov. Ganetespib has received Fast Track designation from FDA for second-line treatment of non-small cell lung adenocarcinoma in combination with docetaxel.

About the GALAXY Program

The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program consists of two randomized trials comparing the combination of ganetespib and docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More information about the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126 and NCT01798485).

About Lung Cancer

Lung cancer is the leading cause of cancer-related death in the world, accounting for nearly 1.4 million deaths in 2008, according to the World Health Organization. The five-year survival rate for this disease is approximately 16%; over half of people with lung cancer die within one year of being diagnosed. In the U.S., the American Cancer Society estimates that 228,000 cases of lung cancer will be diagnosed in 2013. Non-small cell adenocarcinoma comprises about 40% of all lung cancer.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to timing and expected developments in the ganetespib program, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
gfarmer@syntapharma.com
or
Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

ForeverGreen Achieves Key Financial Metrics

OREM, Utah--(BUSINESS WIRE)-- ForeverGreen Worldwide Corporation (FVRG), a leading provider of nutritional foods and other healthy products, today announced that several important financial measurements have recently turned positive for the company.

Recent highlights included:

• Positive EBITDA - positive EBITDA during Q2
• Positive non-GAAP earnings
• Operating Profitability - net cash provided by operating activities of approximately 1½ cents/share during Q2 2013, continues to escalate in Q3 2013
• Revenue increasing - Q3 2013 will be significantly higher than Q3 2012 revenues with higher gross margins.

"We have two major factors that are driving our growth and profitability beyond any prior historical levels. First, we have a Class I FDA listed medical device to market, and secondly we are selling in 136 countries. This number has increased by 119 new countries since the beginning of 2013. Our number of active distributors for just the FG Xpress product is over 13,000, and we are now adding nearly 2,500 new distributors each month. We look forward to continuing to deliver the important metrics our shareholders desire," commented Ron Williams, CEO.

ForeverGreen Worldwide Corporation develops, manufactures and distributes an expansive line of all natural whole foods and products to North America, Australia, Europe, Asia, South America and Africa. Offerings include their new global offering, Power Strips. Additionally, they offer Azul and FrequenSea™ whole-food beverages with industry exclusive Marine Phytoplankton, Versativa line of hemp-based whole-food products, A.I.M. Transfer Factor immune support, 03World™ weight management products, Pulse-8 powdered L-arginine formula, TRUessence™ Essential Oils and Apothecary, 24Karat Chocolate®, and an entire catalog of meals, snacks, household cleaners and personal care products. www.forevergreen.org

Forward-Looking Statement

This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are "forward-looking statements" and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include among others, certain risks associated with the operation of the company described above. The company's actual results could differ materially from expected results.

ForeverGreen Worldwide Corporation
Craig Smith, 801-655-5500
craig@forevergreen.org
or
Brokers and Analysts:
Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com

KEYWORDS:   United States  North America  Utah

INDUSTRY KEYWORDS:

Ares Commercial Real Estate Corporation Closes $37 Million Mezzanine Loan on Downtown Chicago Property

ACRE Has Originated / Co-Originated Over $515 million of Commitments Year-To-Date with Significant Investment Capacity to Make New Loans

CHICAGO--(BUSINESS WIRE)-- Ares Commercial Real Estate Corporation (NYS: ACRE) announced today that it originated a $37.0 million mezzanine loan collateralized by the office and associated parking of a 49-story mixed-use property in the central business district of Chicago. The proceeds of this recently closed transaction were used to refinance the property and fund certain property-level improvements. The property is owned by a joint venture between Walton Street Capital and GlenStar Properties.

"This transaction reflects our ability to finance complex properties and meet the expanding needs of our clients," said Bruce Cohen, President and Chief Operating Officer of Ares Commercial Real Estate Corporation. "We are delighted to back Walton Street Capital and GlenStar Properties as they execute their business plans."

"These recent transactions demonstrate the execution of our capital deployment goals since our equity raise, and we continue to have meaningful investment capacity to make new loans and grow our earning assets," said Todd Schuster, Co-Chief Executive Officer of Ares Commercial Real Estate Corporation. "We believe our current available capital should enable us to make additional senior loans of approximately $300 million."

Ares Commercial Real Estate Corporation's loan portfolio had outstanding principal of approximately $696 million as of August 30, 2013.

About Ares Commercial Real Estate Corporation

Ares Commercial Real Estate Corporation is a specialty finance company that originates, invests in and manages middle-market commercial real estate loans and other commercial real estate investments. Through its national direct origination platform, Ares Commercial Real Estate Corporation provides flexible financing solutions for middle market borrowers. Ares Commercial Real Estate Corporation intends to elect to be taxed as a real estate investment trust and is externally managed by an affiliate of Ares Management LLC, a global alternative asset manager with approximately $66 billion in committed capital under management as of June 30, 2013 and pro forma for the AREA Property Partners acquisition which closed on July 1, 2013. For more information, please visit ACRE's website at arescre.com.

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which relate to future events or our future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. Ares Commercial Real Estate Corporation undertakes no duty to update any forward-looking statements made herein.

Ares Commercial Real Estate Corporation
Carl Drake, 888-818-5298
cdrake@aresmgmt.com

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:

Alexion's Soliris^® (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS

First and Only Approved Treatment in Japan for Patients Suffering from aHUS, a Chronic and Life-Threatening Ultra-Rare Disease

CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NAS: ALXN) , today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of Soliris® (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening ultra-rare disorder. Soliris is already approved in Japan for paroxysmal nocturnal hemoglobinuria (PNH), another severe and ultra-rare disease. Alexion expects that initial patients with aHUS in Japan will commence treatment with Soliris during the fourth quarter of this year.

aHUS is a life-threatening and ultra-rare chronic genetic disease that can progressively damage vital organs, leading to stroke, heart attack, kidney failure, and death.¹ The morbidities and premature mortality in aHUS is caused by chronic uncontrolled activation of the complement system, resulting in thromobotic microangiopathy (TMA, the formation of blood clots in small blood vessels throughout the body).^2,3 Soliris, a first-in-class terminal complement inhibitor, specifically targets uncontrolled complement activation, and is approved for the suppression of TMA in patients with aHUS.

"Soliris has been proven to have a life-transforming impact on patients suffering from aHUS and represents a significant step forward in the treatment of this devastating disease," said Prof. Motoshi Hattori, Professor and Director of the Department of Pediatric Nephrology, Tokyo Women's Medical University of Tokyo Woman's UHP. "Results from clinical studies show that chronic Soliris treatment inhibits complement-mediated TMA which is responsible for thrombosis, vital organ failure, and other life-threatening manifestations of aHUS."

"The approval of Soliris for the treatment of aHUS by the Japanese government brings life-transforming hope to patients suffering from this devastating disease," said David Hallal, Executive Vice President and Chief Commercial Officer of Alexion. "We will initiate our disease awareness and education programs as we work closely with the healthcare community to support rapid and accurate diagnosis of aHUS as well as better informed treatment decisions."

Soliris is also approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory authorities for the treatment of patients with aHUS to inhibit complement-mediated TMA. In addition, Soliris is approved in more than 40 countries, including Japan, for the treatment of patients with PNH, a debilitating, ultra-rare and life-threatening blood disorder.

Clinical Data

Alexion's supplemental new drug application (sNDA) for Soliris in Japan included clinical data from two prospective, controlled, open-label studies in adolescent and adult patients with aHUS, and a third retrospective study in pediatric patients with aHUS, which together included a broad range of aHUS patients in North America and Europe. In these studies, all patients treated with Soliris demonstrated rapid and sustained reduction in terminal complement activity, and chronic administration of Soliris resulted in rapid and sustained reduction in complement-mediated TMA. Soliris was well tolerated in these clinical studies. The most frequently reported adverse events were hypertension, upper respiratory tract infection, and diarrhea. In addition, the sNDA in Japan included data from a retrospective study and from an ongoing prospective study of both pediatric and adult aHUS patients in Japan. Results from these studies demonstrated that the safety and efficacy of Soliris in these Japanese patients with aHUS were consistent with those noted in the clinical studies of Soliris in aHUS patients in North America and Europe.

About aHUS

aHUS is a chronic, ultra-rare, and life-threatening disease in which a genetic deficiency in one or more complement regulatory genes causes chronic uncontrolled complement activation, resulting in complement-mediated thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body.^4,5 Permanent, uncontrolled complement activation in aHUS causes a life-long risk for TMA, which leads to sudden, catastrophic, and life-threatening damage to the kidney, brain, heart, and other vital organs, and premature death.^4,6Sixty-five percent of all patients with aHUS die, require kidney dialysis, or have permanent kidney damage within the first year after diagnosis despite plasma exchange or plasma infusion (PE/PI).^3,7 The majority of patients with aHUS who receive a kidney transplant commonly experience subsequent systemic TMA, resulting in a 90% transplant failure rate in these TMA patients.⁸

aHUS affects both children and adults. Complement-mediated TMA also causes reduction in platelet count (thrombocytopenia) and red blood cell destruction (hemolysis). While mutations have been identified in at least ten different complement regulatory genes, mutations are not identified in 30-50% of patients with a confirmed diagnosis of aHUS.²

About Soliris

Soliris is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris is also approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells).

Soliris is also approved in the US, the European Union, Japan and other territories as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, a debilitating, ultra-rare and life-threatening genetic disorder characterized by complement-mediated thrombotic microangiopathy (blood clots in small vessels). The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Alexion's breakthrough approach in complement inhibition has received the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad implications for future biomedical research and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases.

Important Safety Information

The US product label for Soliris includes a boxed warning: "Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies. Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of developing a meningococcal infection. (See Serious Meningococcal Infections (5.1) for additional guidance on the management of meningococcal infection.) Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-soliris (1-888-765-4747)."

In patients with PNH, the most frequently reported adverse events observed with Soliris treatment in clinical studies were headache, nasopharyngitis (runny nose), back pain and nausea. Soliris treatment of patients with PNH should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. In patients with aHUS, the most frequently reported adverse events observed with Soliris treatment in clinical studies were hypertension, upper respiratory tract infection, diarrhea, headache, anemia, vomiting, nausea, urinary tract infection, and leukopenia. Please see full prescribing information for Soliris, including boxed WARNING regarding risk of serious meningococcal infection.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris^® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 40 countries for the treatment of PNH, and in the United States, Europe, Japan and other territories for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of four other innovative biotechnology product candidates which are being investigated across additional severe and ultra-rare disorders beyond PNH and aHUS. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at www.alexionpharma.com.

[ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris and the timing of regulatory and commercial milestones for Soliris in Japan. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of published reports or clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the risk that clinical trials may not be completed successfully, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Annual Report on Form 10-Q for the period ended June 30, 2013, and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

(1) Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-87.

(2) Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-59.

(3) Caprioli J, Noris M, Brioschi S, et al. The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-9.

(4) Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens. 2010;19(3):242-7.

(5) Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24:687-96.

(6) Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006;70(1):16-23.

(7) Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:673-81.

(8) Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99.

Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Executive Director, Corporate Communications
or
Media:
Alexion Pharmaceuticals, Inc.
Kim Diamond, 203-439-9600
Senior Director, Corporate Communications
or
Investors:
Rx Communications
Rhonda Chiger, 917-322-2569

KEYWORDS:   United States  Asia Pacific  North America  Connecticut  Japan

INDUSTRY KEYWORDS:

OCI Resources LP Prices Initial Public Offering

ATLANTA--(BUSINESS WIRE)-- OCI Resources LP (the "Partnership") (NYS: OCIR) announced today the pricing of its initial public offering of 5,000,000 common units representing limited partner interests in the Partnership at a public offering price of $19.00 per common unit. In addition, the Partnership has granted the underwriters a 30-day option to purchase up to 750,000 additional common units at the initial public offering price. The Partnership's common units are expected to begin trading on the New York Stock Exchange under the symbol "OCIR" on September 13, 2013. The offering is expected to close on September 18, 2013, subject to customary closing conditions.

Upon conclusion of the offering, the public ownership will represent a 25.1% limited partner interest in the Partnership, or a 28.8% limited partner interest in the Partnership if the underwriters exercise their option to purchase additional common units in full. OCI Enterprises Inc., through certain of its subsidiaries, will hold a 2.0% general partner interest and the remaining limited partner interest in the Partnership.

Citigroup and Goldman, Sachs & Co. are acting as joint book-running managers, and Barclays and Credit Suisse are acting as co-managers, of the offering. The offering is being made solely by means of a written prospectus forming part of the effective registration statement. When available, a copy of the final prospectus relating to the offering, which meets the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained from either of the following:

• Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone (800) 831-9146 or by email at batprospectusdept@citi.com; or
• Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, or by telephone (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com.

The registration statement and, when available, the final prospectus, may be obtained, free of charge, at the U.S. Securities and Exchange Commission's (the "SEC") website at www.sec.gov under the registrant's name, "OCI Resources LP."

A registration statement relating to the common units was filed with, and declared effective by, the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the common units referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT OCI RESOURCES LP

OCI Resources LP, a master limited partnership, operates the trona ore mining and soda ash production business of OCI Wyoming, L.P., one of the largest and lowest cost producers of natural soda ash in the world, serving a global market from its facility in the Green River Basin of Wyoming. The facility has been in operation for more than 50 years.

FORWARD-LOOKING STATEMENTS

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Partnership's other filings with the SEC. The Partnership undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

OCI Resources LP
Investor Relations
Scott Humphrey, Director of Investor Relations
770-375-2387
SHumphrey@ocienterprises.com
or
Media
Amy McCool
770-243-9191
AMcCool@ocienterprises.com

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS: